Data analytics firm Palantir (PLTR) is the top-performing stock in the benchmark S&P 500 index so far this year.
Pliant (PLRX) stock plunged 61% on news it has paused enrollment in a Phase 2b study of its drug bexotegrast in patients with ...
We recently compiled a list of the 13 Best Natural Gas and Oil Dividend Stocks To Buy. In this article, we are going to take a look at where BP p.l.c.
Needham analyst Joseph Stringer lowered the firm’s price target on Pliant Therapeutics (PLRX) to $10 from $38 and keeps a Buy rating on the ...
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed ...
Palantir's Q4 earnings beat expectations, with revenue up 36% YoY and EPS up 75% YoY. Check out why I remain bearish on PLTR ...
The result has been tremendous growth. Just four years ago, Palantir had 14 U.S. commercial customers. Today, that number has ...
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results